Audited Financial Result For The Year Ended March 31, 2018
Sub: Audited Financial Result for the year ended March 31, 201829-05-2018
29-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces Poster Presentations on GBR 1302 and GBR 1342, HER2xCD3 and CD38xCD3 Bispecific Antibodies, at the 2018 ASCO Annual Meeting.28-05-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Wednesday, May 30, 2018 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.23-05-2018
Glenmark Pharma submits new drug application for Ryaltris
Glenmark Pharmaceuticals has submitted a new drug application with the US health regulator for its nasal spray Ryaltris, used for the treatment of s22-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces the Company's First New Drug Application Submission for Ryaltris for Patients with Seasonal Allergic Rhinitis.22-05-2018
Glenmark Pharma gets USFDA nod for generic version of Welchol tablets
Glenmark Pharma today said it has received final approval from the US health regulator for Colesevelam Hydrochloride tablets, 625 mg, the generic ve21-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride Tablets, 625 mg21-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting18-05-2018